Perimenopause is the 5–10 year window before the final menstrual period during which hormones shift dramatically — often well before cycles become irregular. It is diagnosed primarily from symptoms and cycle patterns, not from a single lab. Hormones swing widely cycle to cycle during this transition, which is why one "normal" estradiol or FSH does not rule perimenopause out.
Bloodwork is still useful — just not as a yes/no diagnosis. The biomarkers worth discussing with a qualified healthcare provider include FSH and estradiol (with timing caveats), progesterone in the luteal phase if cycles continue, AMH in some contexts, a full thyroid panel (because symptoms overlap with hypothyroid), ferritin (heavy bleeding is common in this window), and cardiometabolic markers like ApoB, hsCRP, fasting insulin and HbA1c, which begin to drift through perimenopause. Vitamin D and B12 round out the standard add-ons. The pattern across markers and time tells the story; a single draw rarely does.
What perimenopause actually is.
Perimenopause is the transition leading up to the final menstrual period (after which the "post-menopause" phase begins). It typically starts in the late 30s to mid-40s and lasts 4–10 years for most women, though both timing and duration vary widely. The defining feature is hormonal volatility — not a steady decline — with estradiol and progesterone swinging more dramatically cycle to cycle than at any other point in the reproductive lifespan.
Symptoms can include cycle changes (shorter, longer, heavier, lighter, skipped), hot flashes, night sweats, sleep disruption, mood shifts, brain fog, joint aches, vaginal and skin dryness, weight redistribution, hair changes, and a meaningful rise in anxiety or low mood. The cluster is wide, individual, and often dismissed for years.
"Perimenopause is one of the most predictable transitions in women's lives, and one of the most often missed. The biology is well-described. The clinical attention is not."
For the broader symptom picture and stage frame, see the perimenopause hub.
Reproductive hormones in perimenopause.
The hormones most often discussed in this window — and the most often misread.
FSH (follicle-stimulating hormone).
FSH rises as the ovaries become less responsive to the pituitary's signals. Elevated baseline FSH (typically drawn on day 2 or 3 of the cycle) is one of the markers used in evaluating perimenopause. But single FSH numbers swing dramatically in this window — a day-3 FSH of 25 mIU/mL one cycle and 10 mIU/mL the next is not unusual. A trend over months tells a more useful story than a single value.
Estradiol (E2).
Counter-intuitively, estradiol does not steadily decline in early perimenopause — it often swings high before it falls. Some women experience the worst symptoms during periods of estrogen excess relative to progesterone, not estrogen deficiency. A single estradiol means little without cycle context. Read more on the estradiol page.
Progesterone.
Progesterone is the hormone that typically declines first and most consistently in perimenopause — anovulatory cycles (cycles without ovulation) become more common, and without ovulation there is no luteal progesterone surge. A luteal-phase progesterone (typically day 21 of a 28-day cycle, or roughly 7 days post-ovulation) is the standard way to evaluate this. See the progesterone page.
AMH (anti-Müllerian hormone) — educational.
AMH is a marker of ovarian reserve. It declines progressively through reproductive life and becomes very low or undetectable around menopause. AMH is most clinically useful in fertility evaluation rather than in perimenopause diagnosis — a low AMH does not mean perimenopause is imminent, and a still-detectable AMH does not rule it out. Useful in context, misleading on its own.
Timing matters more than the number.
Day 3 FSH and estradiol are conventional in fertility evaluation. In perimenopause, a single draw is often less informative than a series across two or three cycles. Progesterone is only meaningful in the luteal phase. None of this is necessary for diagnosis — it is most useful when treatment decisions or fertility questions are on the table.
The perimenopause hub.
Symptoms, stage frame, what's actually shifting and why so much of it gets missed by primary care.
Read next · GuideThyroid panel explained.
Thyroid symptoms overlap heavily with perimenopause symptoms. Why a full panel earns its keep in this window.
Thyroid — the symptom overlap that catches everyone.
Fatigue. Weight changes. Hair shedding. Mood shifts. Cycle irregularity. Brain fog. Cold intolerance. Read that list with hypothyroidism in mind, and it fits. Read it with perimenopause in mind, and it fits. The overlap is almost complete — which is why a full thyroid panel is one of the most useful things to add when perimenopause symptoms start.
The standard TSH-only screen catches overt thyroid disease. It can miss the subclinical and antibody-positive patterns that show up in this same age window — particularly Hashimoto's thyroiditis, which is more common in women and more often missed. The thyroid panel guide walks through the full panel and what each marker adds.
Ferritin and the heavy-bleeding connection.
Perimenopausal cycles often get heavier before they get lighter. Anovulatory cycles can produce prolonged unopposed estrogen, which thickens the endometrial lining and leads to heavier, longer, more clotted bleeding. The downstream effect on iron stores is rarely tracked.
Ferritin sits outside the standard CBC. Many perimenopausal women run low iron stores for years before haemoglobin drops enough to flag anaemia on the CBC. Fatigue, hair shedding and exercise intolerance can sit on top of low ferritin and look entirely like "perimenopause symptoms." For the deeper editorial, see ferritin and heavy periods and the canonical ferritin guide.
The cardiometabolic shift.
The perimenopause window is when several cardiometabolic risk markers begin to drift — and it's also when the standard "lipid panel + TSH" check-up risks missing the early signal.
What tends to move.
- ApoB: the count of cholesterol-carrying particles behind atherosclerotic risk. Often rises through perimenopause even when total cholesterol and LDL look "fine."
- hsCRP: a marker of low-grade systemic inflammation. Tends to drift up in this window.
- Fasting insulin and HbA1c: insulin resistance can creep in well before glucose flags. Visceral adiposity often increases.
- Triglycerides and HDL ratio: a useful insulin-sensitivity proxy, increasingly imbalanced in this window.
- Blood pressure: not bloodwork, but worth tracking alongside.
Cardiovascular disease is the leading cause of death in U.S. women — and risk accelerates after menopause. The perimenopause window is the inflection point. The cardiometabolic hub covers this in depth.
Vitamin D, B12, and the less-obvious markers.
Two more biomarkers worth including in the conversation.
Vitamin D.
Bone density declines accelerate through perimenopause and post-menopause as estrogen falls. Adequate vitamin D status is part of the bone-health picture, alongside calcium, magnesium, weight-bearing exercise and protein intake. See the vitamin D page.
Vitamin B12.
B12 absorption can decrease with age, with proton-pump inhibitor use, and with certain dietary patterns. B12 deficiency symptoms — fatigue, mood, brain fog, tingling — sit comfortably on top of the perimenopause symptom cluster. Easy to screen, often worth checking.
Fasting insulin.
Mentioned above under cardiometabolic, but worth re-flagging — this is often the first marker to drift, and it's almost never on a standard annual panel.
Why your labs "look normal" when you feel different.
This is the single most common frustration in the perimenopause inbox: a full set of labs comes back "all in range," and yet sleep, mood, energy, cycles and weight are visibly off. A few reasons this happens.
Three reasons "normal" can be misleading here.
- Hormones swing. A single estradiol or progesterone in a perimenopausal cycle can land anywhere. The volatility is the story.
- Reference ranges are wide. Ranges are built across all reproductive-age women, including those at peak ovarian function. Sitting in the lower-middle of a 25-year-old reference range may be a meaningful drop from your own previous baseline.
- Symptoms outpace the lab signal. Symptoms can precede measurable cardiometabolic, thyroid or hormone changes by months or years.
None of this means bloodwork is useless. It means the pattern across markers, the trend over time, and the symptom picture matter as much as any single number.
What to bring to your provider.
The most useful inputs are usually: a 3-month cycle tracker (length, flow, symptoms), your last two or three years of labs in one place, and a short list of the symptoms most disrupting daily life. From there, a conversation about which additional labs are worth drawing now — and what intervention frames (lifestyle, hormone therapy, targeted nutrient support) might be on the table — has somewhere to land.
Frequently asked.
Can bloodwork confirm perimenopause?
Generally no — not on its own. Perimenopause is a clinical diagnosis made primarily from symptom pattern and cycle changes. Hormone levels swing widely cycle to cycle during this window, so a single FSH or estradiol can be misleading. Bloodwork is most useful for ruling out other causes of similar symptoms and for tracking trends over time.
What hormones should I test in perimenopause?
If a qualified healthcare provider recommends hormone testing, day 3 FSH and estradiol are most common, with progesterone tested in the luteal phase if cycles continue. AMH is sometimes added in fertility contexts. None of these are definitive on a single draw, which is why they are read alongside symptoms and trends.
Why do my perimenopause labs look normal when I feel terrible?
Hormone levels in perimenopause fluctuate dramatically from cycle to cycle, so a single draw can fall in any direction on any given day. A "normal" result does not rule out perimenopause, and it does not invalidate symptoms. Many clinicians lean more on symptom patterns than on single hormone numbers for diagnosis.
What non-hormone bloodwork matters in perimenopause?
The full thyroid panel, ferritin and iron studies, vitamin D, B12, fasting insulin, HbA1c, ApoB and hsCRP are all worth discussing. Cardiometabolic risk rises during this window, heavy periods can drive iron deficiency, and thyroid symptoms overlap heavily with perimenopause symptoms.
When should I test for perimenopause?
There is no fixed schedule. Many U.S. clinicians wait until symptoms or cycle changes prompt the conversation, typically in the late 30s through 50s. Tracking trends over a year or two — symptoms, cycles and selected labs — is often more useful than a single set of results.
Can hormone testing tell me whether to start HRT?
Not on its own. The decision to consider hormone therapy is based on symptoms, age, time since the last period, individual risk factors and personal preference — not a hormone number. A qualified healthcare provider familiar with menopause care is the right person to have that conversation with.
Sources & further reading
- [Source: clinical society guideline — The Menopause Society (formerly NAMS) position statements on menopause and perimenopause evaluation.]
- [Source: peer-reviewed source — STRAW+10 staging system for reproductive aging (Stages of Reproductive Aging Workshop).]
- [Source: peer-reviewed source on cardiometabolic transition through perimenopause — SWAN study (Study of Women's Health Across the Nation).]
- [Source: clinical society guideline — American Thyroid Association guidelines on thyroid testing in midlife women.]
- [Source: reputable institution — Mayo Clinic or Cleveland Clinic patient-facing explainer on perimenopause and hormone testing.]